.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,233,115

« Back to Dashboard

Claims for Patent: 9,233,115

Title:Proteasome inhibitors and methods of using the same
Abstract: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.
Inventor(s): Bernardini; Raffaella (Calci, IT), Bernareggi; Alberto (Concorezzo, IT), Cassara; Paolo G. (Monza, IT), Chatterjee; Sankar (Wynnewood, PA), D'Arasmo; Germano (Novate Milanese, IT), De Munari; Sergio (Milan, IT), Ferretti; Edmondo (Ravenna, IT), Iqbal; Mohamed (Malvern, PA), Menta; Ernesto (Cemusco sul Naviglio, IT), Messina McLaughlin; Patricia A. (Glen Mills, PA), Oliva; Ambrogio (Saronno, IT)
Assignee: Millennium Pharmaceuticals Inc. (Cambridge, MA)
Application Number:13/949,346
Patent Claims: 1. A method for treating a cancer selected from the group consisting of skin, prostate, colorectal, pancreas, kidney, ovary, mammary, liver, tongue, smooth muscle tissue, leukemia, lymphoma, non-Hodgkin lymphoma, myeloma, and multiple myeloma comprising administering to a mammal having or predisposed to said cancer a therapeutically effective amount of a compound of Formula (I) ##STR00682## or a pharmaceutically acceptable salt, stereoisomeric or tautomeric form thereof, wherein: R.sup.1 is C.sub.1-C.sub.8 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, or C.sub.3-C.sub.7 cycloalkyl; R.sup.2 is H; Q is --B(OH).sub.2, --B(OR.sup.14).sub.2, or a cyclic boronic ester wherein said cyclic boronic ester contains from 2 to 20 carbon atoms, and, optionally, a heteroatom which can be N, S, or O; R.sup.14 is H, C.sub.1-C.sub.4 alkyl, cycloalkyl, cycloalkylalkyl, aryl, or aralkyl; X is R.sup.AC(.dbd.O)--; R.sup.ANHC(.dbd.O)--, R.sup.AS(O).sub.2--, R.sup.ASC(.dbd.O)--, or R.sup.A; R.sup.A is C.sub.1-C.sub.20 alkyl optionally substituted with R.sup.20; C.sub.2-C.sub.20 alkenyl optionally substituted with R.sup.20; C.sub.2-C.sub.20 alkynyl optionally substituted with R.sup.20; carbocyclyl optionally substituted with 1-5 R.sup.22; or heterocarbocyclyl optionally substituted with 1-5 R.sup.22; R.sup.20 is selected from the group consisting of: --OR.sup.20a, --SR.sup.20a--S(.dbd.O)R.sup.20a, --S(.dbd.O).sub.2R.sup.20a, --S(.dbd.O).sub.2NHR.sup.20a, --SC(.dbd.O)R.sup.20a, --C(.dbd.O)R.sup.20a, --C(.dbd.O)NHR.sup.20a, --C(.dbd.O)O--R.sup.20a, phthalimido, --(O-alkyl), --O-alkyl-OH, --(O-alkyl).sub.r-OH, --OR.sup.20c, --SR.sup.20c, --O--alkyl-R.sup.20c, --S(.dbd.O).sub.2--R.sup.20c, --S(.dbd.O).sub.2--NHR.sup.20c, --SC(.dbd.O)R.sup.20c, --C(.dbd.O)R.sup.20c, --C(.dbd.O)OR.sup.20c, --C(.dbd.O)NHR.sup.20c, carbocyclyl optionally substituted with 1-5 R.sup.22; and heterocarbocyclyl optionally substituted with 1-5 R.sup.22; R.sup.20a is C.sub.1-C.sub.20 alkyl, C.sub.2-C.sub.20 alkenyl, or C.sub.2-C.sub.20 alkynyl; wherein said alkyl, alkenyl, or alkynyl is optionally substituted by one or more halo, C.sub.1-C.sub.4 alkyl, aryl, heteroaryl or --NHR.sup.20b; R.sup.20c is carbocyclyl optionally substituted with 1-5 R.sup.22; or heterocarbocyclyl optionally substituted with 1-5 R.sup.22; R.sup.22 is selected from the group consisting of: C.sub.1-C.sub.10 alkyl, C.sub.2-C.sub.10 alkenyl, C.sub.2-C.sub.10 alkynyl, phenyl, halo, haloalkyl, alkoxy, thialkoxy, amino, alkylamino, dialkylamino, carboxyl, alkyl-OC(.dbd.O)--, alkyl-C(.dbd.O)--, aryl-OC(.dbd.O)--, alkyl-OC(.dbd.O)NH--, aryl-OC(.dbd.O)NH--, alkyl-C(.dbd.O)NH--, alkyl-C(.dbd.O)O--, (alkyl-O).sub.r-alkyl, HO-(alkyl-O).sub.r-alkyl-, --OH, --SH, --CN, --N.sub.3, --CNO, --CNS, alkyl-S(.dbd.O)--, alkyl-S(.dbd.O).sub.2--, H.sub.2NS(.dbd.O)--, and H.sub.2NS(.dbd.O).sub.2--; and r is 2, 3, 4, 5, 6, 7, 8, 9, or 10.

2. The method of claim 1, wherein X is R.sup.AC(.dbd.O)--.

3. The method of claim 1, whereinX is R.sup.AC(.dbd.O)-- and R.sup.A is aryl optionally substituted with 1-3 substituents selected from the group consisting of C.sub.1-C.sub.10 alkyl, C.sub.2-C.sub.10 alkenyl, C.sub.2-C.sub.10 alkynyl, halo, haloalkyl, alkoxy, thialkoxy, amino, alkylamino, dialkylamino, alkyl-OC(.dbd.O)--, alkyl-C(.dbd.O)--, alkyl-OC(.dbd.O)NH--, alkyl-C(.dbd.O)NH--, --OH, --CN, alkyl-S(.dbd.O)--, and alkyl-S(.dbd.O).sub.2.

4. The method of claim 1, wherein the cancer is selected from the group consisting of skin, prostate, colorectal, pancreas, kidney, ovary, mammary, liver, tongue, and smooth muscle tissue.

5. The method of claim 1, wherein the cancer is selected from the group consisting of leukemia, lymphoma, non-Hodgkin's lymphoma, myeloma, and multiple myeloma.

6. The method of claim 1, wherein the cancer is multiple myeloma.

7. The method of claim 1, comprising administering the compound in combination with one or more antitumor or anticancer agents and/or radiotherapy.

8. The method of claim 1, wherein the cancer is leukemia.

9. The method of claim 1, wherein the cancer is non-Hodgkin's lymphoma.

10. The method of claim 1, wherein the cancer is lymphoma.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc